Skip to Content

54 Results Found

  • Article
  • Open Access
4 Citations
5,259 Views
14 Pages

A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia

  • Samia Kalsoom,
  • Muhammad Fawad Rasool,
  • Imran Imran,
  • Hamid Saeed and ,
  • Tanveer Ahmad and
  • Faleh Alqahtani
  • + 1 author+ 0 author

19 February 2024

Nadolol is a long-acting non-selective β–adrenergic antagonist that helps treat angina and hypertension. The current study aimed to develop and validate the physiologically based pharmacokinetic model (PBPK) of nadolol in healthy adults, r...

(This article belongs to the Section Pharmacology)
  • Article
  • Open Access
4 Citations
6,163 Views
18 Pages

Background/Objectives: N-acetyl-galactosamine small interfering RNAs (GalNAc-siRNA) are an emerging class of drugs due to their durable knockdown of disease-related proteins. Direct conjugation of GalNAc onto the siRNA enables targeted uptake into he...

(This article belongs to the Special Issue Advancing Biologic Drug Development Through Physiologically Based Pharmacokinetic Modelling and Simulations)
  • Article
  • Open Access
4 Citations
2,210 Views
20 Pages

Background/Objectives: Fixed-dose combinations (FDCs) hold significant clinical value for the management of hypertension, diabetes and other chronic diseases. However, since the complexity of formulations, generic compounds require both in vitro phar...

(This article belongs to the Special Issue In Vitro–In Vivo Correlation and Mechanistic Pharmacokinetic Models: Bridging Drug In Vitro Characteristics and In Vivo Behaviors)
  • Article
  • Open Access
4 Citations
4,935 Views
23 Pages

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations

  • Mohammed S. Alasmari,
  • Fawaz Alasmari,
  • Abdullah F. Alasmari,
  • Aws Alshamsan and ,
  • Sary Alsanea,
  • Muhammad F. Rasool and
  • Faleh Alqahtani
  • + 2 authors+ 0 author

The physiologically based pharmacokinetic (PBPK) approach can be used to develop mathematical models for predicting the absorption, distribution, metabolism, and elimination (ADME) of administered drugs in virtual human populations. Haloperidol is a...

(This article belongs to the Special Issue Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions)
  • Article
  • Open Access
4 Citations
3,252 Views
20 Pages

Introduction/aim: N-acetylgalactoseamine-conjugated small interfering RNAs (GalNAc-siRNAs) are an emerging class of drugs possessing an extensive clinical potential because of their high target specificity to the asialoglycoprotein receptor (ASGPR) i...

(This article belongs to the Special Issue Advancing Biologic Drug Development Through Physiologically Based Pharmacokinetic Modelling and Simulations)
  • Article
  • Open Access
3 Citations
2,860 Views
16 Pages

Background: The drug candidate BI 730357 is a Biopharmaceutics Classification System (BCS) Class II compound showing atypical absorption after oral administration in fasted and fed healthy individuals, for which conventional traditional deconvolution...

(This article belongs to the Special Issue Advances in Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
8 Citations
5,890 Views
17 Pages

Interspecies translation of monoclonal antibodies (mAbs) pharmacokinetics (PK) in presence of target-mediated drug disposition (TMDD) is particularly challenging. Incorporation of TMDD in physiologically based PK (PBPK) modeling is recent and needs t...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
5 Citations
4,211 Views
15 Pages

A Comprehensive Physiologically Based Pharmacokinetic Model for Predicting Vildagliptin Pharmacokinetics: Insights into Dosing in Renal Impairment

  • Mahnoor Pasha,
  • Ammara Zamir,
  • Muhammad Fawad Rasool,
  • Hamid Saeed and ,
  • Tanveer Ahmad,
  • Nawaf Shalih Alqahtani,
  • Lamya Saif Alqahtani and
  • Faleh Alqahtani
  • + 3 authors+ 0 author

Physiologically based pharmacokinetic (PBPK) modeling is of great importance in the field of medicine. This study aims to construct a PBPK model, which can provide reliable drug pharmacokinetic (PK) predictions in both healthy and chronic kidney dise...

(This article belongs to the Section Pharmaceutical Technology)
  • Article
  • Open Access
2 Citations
3,109 Views
17 Pages

Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001)

  • Joo Young Na,
  • Min Hai,
  • Kyeongmin Kim,
  • Sandip M. Vibhute and ,
  • Chad E. Bennett,
  • Christopher C. Coss and
  • Mitch A. Phelps
  • + 2 authors+ 0 author

Background: HOSU-53 (JBZ-001), an orally bioavailable new chemical entity, represents a highly potent dihydroorotate dehydrogenase (DHODH) inhibitor in late preclinical development for application in cancer therapy. Methods: Multiple Good Laboratory...

(This article belongs to the Special Issue In Vitro–In Vivo Correlation and Mechanistic Pharmacokinetic Models: Bridging Drug In Vitro Characteristics and In Vivo Behaviors)
  • Article
  • Open Access
7 Citations
3,739 Views
15 Pages

Pharmacokinetic Modeling of Bepotastine for Determination of Optimal Dosage Regimen in Pediatric Patients with Allergic Rhinitis or Urticaria

  • Sukyong Yoon,
  • Byung Hak Jin,
  • Choon Ok Kim,
  • Kyungsoo Park and ,
  • Min Soo Park and
  • Dongwoo Chae
  • + 1 author+ 0 author

Bepotastine, a second-generation antihistamine for allergic rhinitis and urticaria, is widely used in all age groups but lacks appropriate dosing guidelines for pediatric patients, leading to off-label prescriptions. We conducted this study to propos...

(This article belongs to the Special Issue Model-Informed Drug Discovery and Development, 2nd Edition)
  • Article
  • Open Access
15 Citations
7,663 Views
14 Pages

Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations

  • Hafsa Hafsa,
  • Ammara Zamir,
  • Muhammad Fawad Rasool,
  • Imran Imran and ,
  • Hamid Saeed,
  • Tanveer Ahmad,
  • Sary Alsanea,
  • Ali A. Alshamrani,
  • Abdullah H. Alruwaili and
  • Faleh Alqahtani
  • + 5 authors+ 0 author

Labetalol is a drug that exhibits both alpha and beta-adrenergic receptor-blocking properties. The American Heart Association/American Stroke Association (AHA/ASA) has recommended labetalol as an initial treatment option for the management of severe...

(This article belongs to the Special Issue Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions)
  • Article
  • Open Access
9 Citations
4,259 Views
13 Pages

Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach

  • Faleh Alqahtani,
  • Ali Mohammed Asiri,
  • Ammara Zamir,
  • Muhammad Fawad Rasool and ,
  • Amer S. Alali,
  • Sary Alsanea and
  • Ismail A. Walbi
  • + 2 authors+ 0 author

Hydroxychloroquine (HCQ), a congener of chloroquine, is widely used in prophylaxis and the treatment of malaria, and also as a cure for rheumatoid arthritis, systemic lupus erythematosus, and various other diseases. Physiologically based pharmacokine...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
1 Citations
3,652 Views
16 Pages

A Comprehensive Physiologically Based Pharmacokinetic Framework of Ofloxacin: Predicting Disposition in Renal Impairment

  • Ammara Zamir,
  • Muhammad Fawad Rasool,
  • Iltaf Hussain,
  • Sary Alsanea and ,
  • Samiah A. Alhabardi and
  • Faleh Alqahtani
  • + 1 author+ 0 author

Background: In the last several years, “physiologically based pharmacokinetic (PBPK) modeling” has gathered significant emphasis in the modeling of drug absorption, disposition, and metabolism. This research study aims to elaborate the pl...

(This article belongs to the Special Issue Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and Applications)
  • Article
  • Open Access
1 Citations
906 Views
17 Pages

Development and Evaluation of Physiologically Based Pharmacokinetic (PBPK) Models to Investigate the Effect of CYP2D6 Polymorphism on Metoclopramide Systemic Exposure

  • Iqra Shahzad,
  • Ammara Zamir,
  • Muhammad Fawad Rasool,
  • Amer S. Alali and ,
  • Iltaf Hussain and
  • Faleh Alqahtani
  • + 1 author+ 0 author

17 July 2026

Background: Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic tool used to predict how a drug moves through the body by incorporating real human physiology, including organ sizes, blood flows, tissue compositions, and enzyme acti...

(This article belongs to the Special Issue Population Pharmacokinetics and Pharmacogenetics, 2nd Edition)
  • Article
  • Open Access
669 Views
20 Pages

Development and Evaluation of Physiologically Based Pharmacokinetic (PBPK) Models of Metoclopramide Across the Lifespan: Translation from Adults to Infants

  • Iqra Shahzad,
  • Ammara Zamir,
  • Muhammad Fawad Rasool,
  • Ali A. Alshamrani and ,
  • Iltaf Hussain and
  • Faleh Alqahtani
  • + 1 author+ 0 author

17 September 2026

Background: Physiologically based pharmacokinetic (PBPK) modeling is an established approach used in recent years for estimating drug disposition in challenging clinical scenarios where in vivo studies are difficult to perform. Metoclopramide is a be...

(This article belongs to the Section Pharmacology)
  • Article
  • Open Access
5 Citations
5,057 Views
15 Pages

27 April 2025

Background: Lamotrigine plays a crucial role in the treatment of epilepsy and bipolar disorder in adults and children. However, its pharmacokinetic (PK) behavior in first or long-term treatment in pediatric patients and the changes in drug exposure i...

(This article belongs to the Special Issue Innovative Tools for Drug Analysis and Therapeutic Drug Monitoring (TDM))
  • Article
  • Open Access
18 Citations
4,724 Views
19 Pages

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients

  • Bettina Gerner,
  • Fatemeh Aghai-Trommeschlaeger,
  • Sabrina Kraus,
  • Götz Ulrich Grigoleit and ,
  • Sebastian Zimmermann,
  • Max Kurlbaum,
  • Hartwig Klinker,
  • Nora Isberner and
  • Oliver Scherf-Clavel
  • + 4 authors+ 0 author

Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal i...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
14 Citations
7,659 Views
16 Pages

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. Tegoprazan is mainly metabolized by cytochrome P450 (CYP) 3A4...

(This article belongs to the Special Issue The Role of Pharmacometrics in Drug Discovery and Development Process (Volume II))
  • Review
  • Open Access
21 Citations
10,493 Views
16 Pages

Purpose: To review in vitro testing and simulation platforms that are in current use to predict in vivo performances of generic products as well as other situations to provide evidence for biowaiver and support drug formulations development. Methods:...

(This article belongs to the Special Issue Mechanistic In Vitro and In Silico Modeling of Oral Drug Absorption)
  • Article
  • Open Access
3 Citations
3,130 Views
17 Pages

Background: Diphenhydramine is an anti-tussive used periodically to treat seasonal colds, contact dermatitis, and anaphylactic reactions. This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of diphenhydramine in predictin...

(This article belongs to the Special Issue Precision Dosing in Clinical Therapeutics: The Application of Pharmacokinetics and Pharmacometrics)
  • Article
  • Open Access
3 Citations
4,631 Views
17 Pages

18 March 2025

Background: Tofacitinib is mainly used in the adult population for immune-mediated inflammatory diseases. There is little information available on the pharmacokinetics of tofacitinib in pediatric patients, populations with hepatic impairment and rena...

(This article belongs to the Section Pharmacology)
  • Article
  • Open Access
11 Citations
7,259 Views
16 Pages

A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients

  • Faleh Alqahtani,
  • Abdullah H. Alruwaili,
  • Mohammed S. Alasmari,
  • Sultan A. Almazroa and ,
  • Khaled S. Alsuhaibani,
  • Muhammad F. Rasool,
  • Abdulkarim F. Alruwaili and
  • Sary Alsanea
  • + 3 authors+ 0 author

6 December 2023

Introduction: Ondansetron is a drug that is routinely prescribed for the management of nausea and vomiting associated with cancer, radiation therapy, and surgical operations. It is mainly metabolized in the liver, and it might accumulate in patients...

(This article belongs to the Section Pharmacology)
  • Article
  • Open Access
30 Citations
9,118 Views
20 Pages

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients

  • Lukas Kovar,
  • Andreas Weber,
  • Michael Zemlin,
  • Yvonne Kohl and ,
  • Robert Bals,
  • Bernd Meibohm,
  • Dominik Selzer and
  • Thorsten Lehr
  • + 3 authors+ 0 author

Fentanyl is widely used for analgesia, sedation, and anesthesia both in adult and pediatric populations. Yet, only few pharmacokinetic studies of fentanyl in pediatrics exist as conducting clinical trials in this population is especially challenging....

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
15 Citations
8,784 Views
19 Pages

Trimethoprim is a frequently-prescribed antibiotic and therefore likely to be co-administered with other medications, but it is also a potent inhibitor of multidrug and toxin extrusion protein (MATE) and a weak inhibitor of cytochrome P450 (CYP) 2C8....

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
30 Citations
7,135 Views
19 Pages

Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3...

(This article belongs to the Special Issue Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
24 Citations
11,774 Views
22 Pages

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators

  • Fatima Zahra Marok,
  • Jan-Georg Wojtyniak,
  • Laura Maria Fuhr,
  • Dominik Selzer and ,
  • Matthias Schwab,
  • Johanna Weiss,
  • Walter Emil Haefeli and
  • Thorsten Lehr
  • + 3 authors+ 0 author

The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–drug interaction (DDI) potential. Some of k...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
10 Citations
4,727 Views
20 Pages

Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models

  • Alexander Denninger,
  • Tim Becker,
  • Ulrich Westedt and
  • Karl G. Wagner

Coupling biorelevant in vitro dissolution with in silico physiological-based pharmacokinetic (PBPK) tools represents a promising method to describe and predict the in vivo performance of drug candidates in formulation development including non-passiv...

(This article belongs to the Special Issue Recent Advances in Oral Biopharmaceutics)
  • Article
  • Open Access
19 Citations
7,103 Views
19 Pages

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling

  • Laura Maria Fuhr,
  • Fatima Zahra Marok,
  • Maximilian Mees,
  • Felix Mahfoud and ,
  • Dominik Selzer and
  • Thorsten Lehr
  • + 1 author+ 0 author

The antihypertensive felodipine is a calcium channel blocker of the dihydropyridine type, and its pharmacodynamic effect directly correlates with its plasma concentration. As a sensitive substrate of cytochrome P450 (CYP) 3A4 with high first-pass met...

(This article belongs to the Special Issue Dose-Dependent Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
69 Citations
13,304 Views
19 Pages

The anticonvulsant carbamazepine is frequently used in the long-term therapy of epilepsy and is a known substrate and inducer of cytochrome P450 (CYP) 3A4 and CYP2B6. Carbamazepine induces the metabolism of various drugs (including its own); on the o...

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
26 Citations
9,689 Views
19 Pages

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

  • Nina Hanke,
  • Denise Türk,
  • Dominik Selzer,
  • Sabrina Wiebe and ,
  • Éric Fernandez,
  • Peter Stopfer,
  • Valerie Nock and
  • Thorsten Lehr
  • + 3 authors+ 0 author

The calcium channel blocker and antiarrhythmic agent verapamil is recommended by the FDA for drug–drug interaction (DDI) studies as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor. The purpose of the presented work wa...

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
1,220 Views
19 Pages

Physiologically Based Pharmacokinetic–Pharmacodynamic-Based Quantification of Exposure–Response for Sodium Tanshinone IIA Sulfonate in Normal and Cerebral Ischemia–Reperfusion Injury Rats

  • Ying Chen,
  • Jinyao Zhang,
  • Yongkang Zhang,
  • Tian Qin and ,
  • Weifeng Jin,
  • Yifei Wang,
  • Yunxiang Chen,
  • Li Yu and
  • Lijiang Zhang
  • + 4 authors+ 0 author

24 May 2026

Sodium tanshinone IIA sulfonate (STS) injection is clinically used to protect against cerebral ischemia–reperfusion injury (CIRI). This study aimed to establish physiologically based pharmacokinetic–pharmacodynamic (PBPK–PD) models...

(This article belongs to the Section Medical Biology)
  • Article
  • Open Access
8 Citations
3,039 Views
13 Pages

In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease

  • Man Su,
  • Xianru Liu,
  • Yuru Zhao,
  • Yatong Zhu and ,
  • Mengqiu Wu,
  • Kun Liu,
  • Gangqiang Yang,
  • Wanhui Liu and
  • Lin Wang
  • + 4 authors+ 0 author

27 December 2023

Acute kidney injury (AKI) and chronic kidney disease (CKD) have become public health problems due to high morbidity and mortality. Currently, drugs recommended for patients with AKI or CKD are extremely limited, and candidates based on a new mechanis...

(This article belongs to the Special Issue The Application of LC-MS in Pharmaceutical Analysis)
  • Article
  • Open Access
14 Citations
6,118 Views
20 Pages

Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone

  • Simeon Rüdesheim,
  • Dominik Selzer,
  • Thomas Mürdter,
  • Svitlana Igel and ,
  • Reinhold Kerb,
  • Matthias Schwab and
  • Thorsten Lehr
  • + 2 authors+ 0 author

The cytochrome P450 2D6 (CYP2D6) genotype is the single most important determinant of CYP2D6 activity as well as interindividual and interpopulation variability in CYP2D6 activity. Here, the CYP2D6 activity score provides an established tool to categ...

(This article belongs to the Section Clinical Pharmaceutics)
  • Article
  • Open Access
18 Citations
9,401 Views
22 Pages

The antiplatelet agent clopidogrel is listed by the FDA as a strong clinical index inhibitor of cytochrome P450 (CYP) 2C8 and weak clinical inhibitor of CYP2B6. Moreover, clopidogrel is a substrate of—among others—CYP2C19 and CYP3A4. This...

(This article belongs to the Special Issue Drug–Drug Interactions (Volume II))
  • Article
  • Open Access
4 Citations
2,123 Views
15 Pages

PBPK/PD Model of Vancomycin in Sepsis: Linking Interstitial Exposure in Perfusion-Limited Tissues to MRSA Infection

  • Laura Ben Olivo,
  • Jéssica Luísa Silva de Lemos,
  • Vinicius Jardim Rodrigues,
  • Dúnia Batirola Kretschmer and ,
  • William de Avila Cruz,
  • Keli Jaqueline Staudt,
  • Pieter Annaert and
  • Bibiana Verlindo de Araújo
  • + 3 authors+ 0 author

Objective: This study aims to evaluate free vancomycin concentrations in tissues of septic patients that received empirical doses. Methods: A PBPK model was built in PK-Sim to simulate vancomycin concentrations in healthy volunteers and septic patien...

(This article belongs to the Special Issue Pathophysiological Influences on Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
18 Citations
15,052 Views
22 Pages

The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug interaction (DDI) studies. The aim of this study was to build a whole-body p...

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
2 Citations
2,601 Views
20 Pages

Background/Objectives: Etrasimod is a newly FDA-approved Sphingosine-1-Phosphate modulator indicated for moderate and severe ulcerative colitis. It is extensively metabolized in the liver via the cytochrome P450 system and may accumulate markedly in...

(This article belongs to the Special Issue Precision Dosing in Clinical Therapeutics: The Application of Pharmacokinetics and Pharmacometrics)
  • Article
  • Open Access
2 Citations
2,253 Views
18 Pages

Background/Objectives: Digoxin is a cardiotonic agent with a narrow therapeutic window and a high risk of toxicity. The current clinical use is based on an empirically FDA-recommended regimen which has wide dosing ranges, introducing the risk of inap...

(This article belongs to the Special Issue Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and Applications)
  • Article
  • Open Access
1,717 Views
21 Pages

Physiology-Based Pharmacokinetic Modeling for Prediction of Gentamicin Plasma Profile in Dogs with Renal Dysfunction

  • Kevellyn Silveira Gomes Martins,
  • Lucas Wamser Fonseca Gonzaga,
  • Larissa Alexsandra Felix,
  • Reiner Silveira de Moraes and ,
  • Priscylla Tatiana Chalfun Guimarães Okamoto and
  • Marcos Ferrante
  • + 1 author+ 0 author

Background/Objectives: The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model to predict gentamicin therapeutic protocols for dogs with varying degrees of renal function impairment, considering the minimum inhibitory...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
4 Citations
4,066 Views
18 Pages

In this study, a physiologically based pharmacokinetic (PBPK) modeling framework was employed to explore infliximab exposure following intravenous (5 mg/kg) and subcutaneous administration (encompassing the approved 120 mg flat-fixed dose as a switch...

(This article belongs to the Special Issue Crohn's Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches (2nd Edition))
  • Article
  • Open Access
1,759 Views
15 Pages

Background/Objectives: Tofacitinib is a Janus kinase 1 and 3 inhibitor that was developed to treat rheumatoid arthritis. Accordingly, this study aimed to predict plasma tofacitinib concentrations and pharmacokinetic parameters in patients with renal...

(This article belongs to the Special Issue Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and Applications)
  • Article
  • Open Access
5 Citations
9,436 Views
24 Pages

Background/Objectives: Venlafaxine (VEN) is commonly used in young and elderly patients. Bupropion (BUP) is occasionally added to depression treatments with VEN. BUP’s inhibitory potential toward CYP2D6, VEN’s main metabolic pathway, may...

(This article belongs to the Special Issue Pathophysiological Influences on Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
1 Citations
3,805 Views
17 Pages

Background/Objectives: Colorectal cancer (CRC) holds the third and second position among cancers affecting men and women, respectively. Frequently, the first-line treatment for metastatic CRC consists of the intravenous administration of 5-fluorourac...

(This article belongs to the Special Issue Development of Physiologically Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
1,626 Views
14 Pages

Objectives: The co-administration of Bruton’s tyrosine kinase (BTK) inhibitors with antiretroviral drugs is challenging due to potential drug–drug interactions (DDIs). However, clinical trials specifically assessing such DDIs are lacking....

(This article belongs to the Special Issue Recent Advances in Physiologically Based Pharmacokinetics)
  • Article
  • Open Access
3 Citations
4,031 Views
17 Pages

Amikacin Dosing Adjustment in Critically Ill Oncologic Patients: A Study with Real-World Patients, PBPK Analysis, and Digital Twins

  • Juliana Queiroz da Silva,
  • Natália Valadares de Moraes,
  • Rita Estrela,
  • Diogenes Coelho and ,
  • Diego Feriani,
  • Karen Migotto,
  • Pedro Caruso,
  • Ivan Leonardo França e Silva,
  • Daiane de Araujo Oliveira and
  • Fernanda de Lima Moreira
  • + 6 authors+ 1 author

Background/Objectives: Guidelines recommend adjusting amikacin dosing based on patients’ renal function. Nevertheless, for critically ill cancer patients, the renal function equations based on serum creatinine levels have low or no correlation...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
1 Citations
1,353 Views
18 Pages

Objective: Posaconazole, a second-generation triazole antifungal used for the prevention or treatment of invasive fungal infections, has been shown to markedly increase tacrolimus exposure in vivo when co-administered, potentially leading to clinical...

(This article belongs to the Section Clinical Pharmaceutics)
  • Article
  • Open Access
17 Citations
5,906 Views
18 Pages

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations

  • Hyeon-Cheol Jeong,
  • Min-Gul Kim,
  • Zhuodu Wei,
  • Kyeong-Ryoon Lee and ,
  • Jaehyeok Lee,
  • Im-Sook Song and
  • Kwang-Hee Shin
  • + 2 authors+ 0 author

A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for tegoprazan and its major metabolite M1 was developed to predict PK and PD profiles under various scenarios. The PBPK model for tegoprazan and M1 was developed and predicted u...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
9 Citations
5,045 Views
17 Pages

Building a Human Physiologically Based Pharmacokinetic Model for Aflatoxin B1 to Simulate Interactions with Drugs

  • Orphélie Lootens,
  • Marthe De Boevre,
  • Jia Ning,
  • Elke Gasthuys and ,
  • Jan Van Bocxlaer,
  • Sarah De Saeger and
  • An Vermeulen
  • + 2 authors+ 0 author

Mycotoxins such as aflatoxin B1 (AFB1) are secondary fungal metabolites present in food commodities and part of one’s daily exposure, especially in certain regions, e.g., sub-Saharan Africa. AFB1 is mostly metabolised by cytochrome P450 (CYP) e...

(This article belongs to the Special Issue Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions)
  • Article
  • Open Access
18 Citations
7,550 Views
13 Pages

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation

  • Deok Yong Yoon,
  • SeungHwan Lee,
  • In-Jin Jang,
  • Myeongjoong Kim and ,
  • Heechan Lee,
  • Seokuee Kim,
  • Bongtae Kim,
  • Geun Seog Song and
  • Su-jin Rhee
  • + 4 authors+ 0 author

This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of tegoprazan and to predict the drug–drug interaction (DDI) potential between tegoprazan and cytochrome P450 (CYP) 3A4 perpetrators. The PBPK model of tegoprazan was de...

  • Article
  • Open Access
4 Citations
6,669 Views
12 Pages

26 February 2023

Tegoprazan is a novel potassium-competitive acid blocker. This study investigated the effect of drug–drug interaction on the pharmacokinetics and pharmacodynamics of tegoprazan co-administered with amoxicillin and clarithromycin, the first-line...

(This article belongs to the Section Pharmaceutical Technology)

of 2